{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T17:23:19Z","timestamp":1792516999690,"version":"4.5.0"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8,15]]},"abstract":"<jats:p>\n                    Prostate cancer (PCa) remains a leading cause of cancer-related mortality among men. Although prostate-specific antigen (PSA) is a key biomarker, its diagnostic and prognostic limitations necessitate the identification of novel markers. Urotensin-2 (UT-2), a potent vasoactive peptide, has been implicated in the pathogenesis of several malignancies, but its role in prostate cancer remains underexplored. This study aimed to evaluate plasma UT-2 levels across disease stages in PCa and assess its potential as a biomarker for metastatic disease. This cross-sectional study included 147 male patients: 100 with metastatic PCa and 47 controls (comprising benign prostatic hyperplasia [BPH], localized, and locally advanced PCa). Plasma UT-2 levels were quantified using ELISA. Statistical analyses included analysis of variance, Kruskal\u2013Wallis, and receiver operating characteristic (ROC) curve analysis to assess UT-2\u2019s discriminative ability and its correlation with clinical parameters such as Gleason score, ISUP grade, and PSA. UT-2 levels were significantly elevated in metastatic PCa patients (mean: 2.03\u2005\u00b1\u20050.91\u2009ng\/mL) compared to control groups (BPH: 1.42\u2005\u00b1\u20050.61\u2009ng\/mL; localized: 1.46\u2005\u00b1\u20050.71\u2009ng\/mL; locally advanced: 1.41\u2005\u00b1\u20050.76\u2009ng\/mL;\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005=\u2005.002). ROC analysis demonstrated a moderate discriminatory ability for metastasis (AUC\u2005=\u20050.70, 95% CI: 0.61\u20130.79), with a cutoff of 1.269\u2009ng\/mL yielding 81% sensitivity and 53% specificity. No significant associations were observed between UT-2 levels and Gleason score, ISUP grade, PSA levels, or metastatic site. This is the first clinical study to evaluate plasma UT-2 levels in PCa patients. Elevated UT-2 levels in metastatic cases, independent of traditional prognostic markers, suggest its potential utility in identifying systemic disease burden. While not suitable as a standalone diagnostic tool, UT-2 may serve as a complementary biomarker within a multiparameter panel to improve prognostication and risk stratification in PCa. Further prospective and longitudinal studies are warranted to validate its prognostic significance.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000043848","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T19:00:30Z","timestamp":1755543630000},"page":"e43848","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Plasma urotensin-2 levels as a potential biomarker in prostate cancer: Analysis across disease stages"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0780-295X","authenticated-orcid":false,"given":"Cigdem","family":"Dinckal","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Kars Harakani State Hospital, Kars, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeynep Gulsum","family":"Guc","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huriye","family":"Erbak Yilmaz","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4905-1602","authenticated-orcid":false,"given":"Mustafa","family":"Dinckal","sequence":"additional","affiliation":[{"name":"Department of Urology, Kars Harakani State Hospital, Kars, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semiha","family":"Ozgul","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gamze","family":"Ozkan","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasim Emre","family":"Ergun","sequence":"additional","affiliation":[{"name":"Department of Urology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa Serdar","family":"Kalemci","sequence":"additional","affiliation":[{"name":"Department of Urology, Ege University Faculty of Medicine, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinan","family":"Unal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasar","family":"Yildiz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utku","family":"Oflazoglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarik","family":"Salman","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Economy University Medical Point Hospital, Izmir, Turkey."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmet","family":"Alacacioglu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuksel","family":"Kucukzeybek","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ataturk Training and Research Hospital, Izmir Katip Celebi University, Izmir, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260911","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 Cancers in 185 Countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/iju.13326","article-title":"Novel biomarkers for prostate cancer: an evidence-based review for use in clinical practice.","volume":"24","author":"Narayan","year":"2017","journal-title":"Int J Urol"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fendo.2017.00076","article-title":"The G protein-coupled receptor UT of the neuropeptide urotensin II displays structural and functional chemokine features.","volume":"8","author":"Castel","year":"2017","journal-title":"Front Endocrinol"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2174\/1389203718666170829162335","article-title":"Urotensin II: molecular mechanisms of biological activity.","volume":"19","author":"Svistunov","year":"2018","journal-title":"Curr Protein Pept Sci"},{"key":"R5-20260911","first-page":"533","article-title":"Neurohormones from fish tails: the caudal neurosecretory system. I. \u2018Urophysiology\u2019 and the caudal neurosecretory system of fishes.","volume":"41","author":"Bern","year":"1985","journal-title":"Recent Prog Horm Res"},{"key":"R6-20260911","first-page":"1179","article-title":"Expression of urotensin II and its receptor in human lung adenocarcinoma A549 cells and the effect of urotensin II on lung adenocarcinoma growth in vitro and in vivo.","volume":"24","author":"Wu","year":"2010","journal-title":"Oncol Rep"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/eci.12231","article-title":"Urotensin-II receptor is overexpressed in colon cancer cell lines and in colon carcinoma in humans.","volume":"44","author":"Federico","year":"2014","journal-title":"Eur J Clin Invest"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.3892\/ol.2017.6545","article-title":"Urotensin II receptor as a potential biomarker for the prognosis of hepatocellular carcinoma patients.","volume":"14","author":"Wei","year":"2017","journal-title":"Oncol. Lett"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1756-9966-33-48","article-title":"Urotensin II receptor determines prognosis of bladder cancer regulating cell motility\/invasion.","volume":"33","author":"Franco","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1002\/jcb.22933","article-title":"Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.","volume":"112","author":"Grieco","year":"2011","journal-title":"J Cell Biochem"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/pros.23734","article-title":"Urotensin II receptor expression in prostate cancer patients: a new possible marker.","volume":"79","author":"Giulianelli","year":"2019","journal-title":"Prostate"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0196-9781(01)00441-7","article-title":"Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells.","volume":"22","author":"Takahashi","year":"2001","journal-title":"Peptides"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/S0196-9781(03)00039-1","article-title":"Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II.","volume":"24","author":"Takahashi","year":"2003","journal-title":"Peptides"},{"key":"R14-20260911","first-page":"1419","article-title":"The relationship between Urotensin II and its receptor and the clinicopathological parameters of breast cancer.","volume":"20","author":"Balakan","year":"2014","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1751-7176.2010.00336.x","article-title":"Raised plasma Urotensin II in Type 2 diabetes patients is associated with the metabolic syndrome phenotype.","volume":"12","author":"Gruson","year":"2010","journal-title":"J Clin Hypertension"},{"key":"R16-20260911","doi-asserted-by":"crossref","first-page":"e81764","DOI":"10.1371\/journal.pone.0081764","article-title":"Association between Human Urotensin II and essential hypertension\u2014A 1:1 matched case-control study.","volume":"8","author":"Peng","year":"2013","journal-title":"PLoS One"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1113\/EP087366","article-title":"Urotensin II in the development and progression of chronic kidney disease following \u215a nephrectomy in the rat.","volume":"104","author":"Eyre","year":"2019","journal-title":"Exp Physiol"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"P203","DOI":"10.1186\/cc2092","article-title":"Plasma levels of urotensin II are increased in patients with three-vessel coronary artery disease and left ventricular dysfunction.","volume":"7","author":"Heringlake","year":"2003","journal-title":"Crit Care"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00228-006-0252-6","article-title":"Does cigarette smoking increase plasma urotensin II concentrations?","volume":"63","author":"Gold","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1007\/s13277-015-3082-2","article-title":"The role of the UTS2 gene polymorphisms and plasma Urotensin-II levels in breast cancer.","volume":"36","author":"Yumrutas","year":"2015","journal-title":"Tumor Biol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:01:56Z","timestamp":1789153316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000043848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":20,"journal-issue":{"issue":"33","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000043848","relation":{},"ISSN":["1536-5964","0025-7974"],"issn-type":[{"value":"1536-5964","type":"electronic"},{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"2025-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}